| Diabetic Macular Edema |
ACTRN12618000079246: The Influence of Serum and Aqueous Cytokine Concentrations on the Efficacy of Intravitreal Ranibizumab for the Treatment of Diabetic Macular Oedema |
|
|
| Not yet recruiting | 4 | 60 | | | The Centre for Eye Research Australia , Juvenile Diabetes Research Foundation | Diabetic Macular Oedema | | | | |
ACTRN12614001307695: Intravitreal Aflibercept for the Treatment of Treatment Resistant Diabetic Macular Oedema |
|
|
| Recruiting | 4 | 50 | | | Andrew Chang, Andrew Chang, primary investigator | Diabetic Macular Oedema | | | | |
ACTRN12619000963123: Aflibercept for Diabetic Macular Oedema: Outcomes Using a Treat and Extend Protocol |
|
|
| Recruiting | 4 | 50 | | | The Royal Adelaide Hospital, Bayer Australia Limited | Diabetic Macular Oedema | | | | |
ChiCTR-TRC-11001151: Clinical studies of the Subliminal Micro-Pulse Laser and Argon ion laser in the treatment of diabetic macular edema |
|
|
| Completed | 4 | 120 | | Argon ion laser treatment ;treatment group with threshold of 5% duty cycle micro pulse diode laser photocoagulation ;treatment group with threshold of 10% duty cycle micro pulse diode laser photocoagulation | The First Affiliated Hospital of Xinjiang Medical University; Science and Technology Bureau in Urumqi, Xinjiang; Eye ENT Hospital in Urumqi, Science and Technology Bureau in Urumqi, Xinjiang; special fund of the evidence-based medicine in the first affiliated hospital of Xinjiang Medical University | Diabetic macular edema | | | | |
2013-000133-12: A randomized controlled multicentre study to assess the non-inferiority of the safety of bevacizumab compared to ranibizumab administered by intravitreal injection in patients with macular degeneration or other exudative not age-related macular Studio randomizzato controllato multicentrico per valutare la non-inferiorità della sicurezza di bevacizumab rispetto a ranibizumab somministrati per via intravitreale in pazienti con degenerazione maculare senile o altre maculopatie essudative non correlate all’età |
|
|
| Ongoing | 4 | 1780 | Europe | Concentrate for solution for infusion, Solution for injection, AVASTIN, LUCENTIS | Azienda Ospedaliera Universitaria Integrata Verona, Azienda Ospedaliera Universitaria Integrata Verona | - Age-related macular degeneration - Diabetic retinal oedema - Retinal perivascular sheathing - Choroidal neovascularisation - degenerazione maculare senile essudativa - edema maculare diabetico - edema maculare da occlusione venosa centrale o di branca - neovascolarizzazioni coroideali, - Age-related macular degeneration - Diabetic retinal oedema - Retinal perivascular sheathing - Choroidal neovascularisation - degenerazione maculare senile essudativa - edema maculare diabetico - edema maculare da occlusione venosa centrale o di branca - neovascolarizzazioni coroideali, Diseases [C] - Eye Diseases [C11] | | | | |
2015-000959-24: Investigation of Eylea for patients with diabetic macular edema in an outpatient Setting. |
|
|
| Ongoing | 4 | 50 | Europe | Eylea, Injection, Eylea | Abteilung für Augenheilkunde, AKH Linz, Bayer | Diabetic Retinopathy and diabetic macular edema are leading causes for visual loss and blindness in young adults around the world., Diabetic Macular Edema, Diseases [C] - Eye Diseases [C11] | | | | |
2014-005700-24: Cytokine Levels within patients with diabetic macular edema. |
|
|
| Ongoing | 4 | 20 | Europe | Lucentis, Ozurdex, EMEA/H/C/000715, EU/1/10/638/001, Injection, Intravitreal implant in applicator, Lucentis, Ozurdex | Abteilung für Augenheilkunde, AKH Linz, Bayer | Diabetic Retinopathy and diabetic macular edema are leading causes for visual loss and blindness in young adults around the world., Diabetic Macular Edema, Diseases [C] - Eye Diseases [C11] | | | | |
NCT05715385: Comparison of Treatments in Diabetic Macular Edema |
|
|
| Completed | 4 | 60 | NA | laser photocoagulation, eye drop bromfenac 0.09%, Placebo | Babasaheb Ambedkar Memorial Hospital | Diabetic Macular Edema | 10/15 | 10/15 | | |
2012-000765-20: Silmän sisäisten lääkeainepistosten aikaan saama hermoston uudelleen muokaantuvuus Silmän sisäisten lääkeainepistosten aikaan saama hermoston uudelleen muokaantuvuus |
|
|
| Ongoing | 4 | 40 | Europe | Bevacizumab, RO4876646/F02, Concentrate for solution for infusion, Avastin | Kuopion yliopistollinen sairaala/silmätautien poliklinikka, Kuopion yliopistollinen sairaala | Wet age-related macular degeneration, diabetic macular edema, central retinal vein occlusion, Wet age-related macular degeneration, diabetic macular edema, central retinal vein occlusion, Body processes [G] - Ocular Physiological Phenomena [G14] | | | | |
2005-000397-45: Randomised Controlled Trial Of Intravitreal Triamcinolone In Patients With Diabetic Macular Oedema Refractory To Laser Treatment |
|
|
| Ongoing | 4 | 40 | Europe | kenalog, kenalog, kenalog | Queen\'s Medical centre | Diabetic macular oedema affecting vision and refractory to laser treatment | | | | |
2004-005043-97: A Pilot study investigating the use of Intravitreal Triamcinolone prior to macular laser for Clinically Significant Diabetic Macular Oedema |
|
|
| Ongoing | 4 | 50 | Europe | Triamcinolone Acetonide, Kenalog, Kenalog | St Mary\'s NHS Trust | Macular oedema affects 29% of diabetic patients and is the main cause of visual impairment. Previous studies show that diffuse macular oedema carries a particularly poor prognosis despite laser photocoagulation. | | | | |
2009-017540-13: A Phase IV Open-Labelled Prospective Pilot Study of Intravitreal Macugen (pegaptanib) for Ischaemic Diabetic Macular Oedema (MIDME study) |
|
|
| Ongoing | 4 | 30 | Europe | Pegaptanib sodium 0.3mg, Macugen 0.3mg, Macugen 0.3mg | Clinical Trials and Research Governance | Ischaemic diabetic macular oedema. | | | | |
2011-004613-17: The effect of Lucentis (ranibizumab) on retinal function in diabetic patients with visual impairment and diabetic svelling of the makula Effekt av Lucentis ( ranibizumab), givet i glaskroppen i ögat, på näthinnans funktion hos diabetiker med synnedsättning och svullnad i gula fläcken |
|
|
| Ongoing | 4 | 20 | Europe | LUCENTIS, LUCENTIS (ranibizumab), LUCENTIS (ranibizumab) | Inst of Ophtalmology Lund University hospital, Novartis Sverige AB | Diabetic makula edema with visual impairment Diabetes makula ödem med synnedsättning | | | | |
2016-004488-38: Investigation of the influence of the corticosteroid agent Iluvien on inflammation and growth factors in the eye of patients suffering from diabetic-related retina damage with swelling of the centre of the retina Untersuchung des Einflusses des Kortikosteroid-Medikamentes Iluvien auf die Entzündungs- und Wachstumsfaktoren im Auge von Patienten, die untereiner Diabetes-bedingten Netzhautschädigung mit Schwellung der Netzhautmitte leiden |
|
|
| Ongoing | 4 | 12 | Europe | Intravitreal implant in applicator, ILUVIEN 190 Mikrogramm intravitreales Implantat im Applikator | J. W. Goethe University, represented by dean of the medical faculty, Alimera Sciences Ophthalmologie GmbH | Diabetic related Macula edema Diabetisches Makulaödem, Diabetic-related retina damage with swelling of retina centre Diabetes-bedingte Netzhautschädigung mit Schwellung der Netzhautmitte, Diseases [C] - Eye Diseases [C11] | | | | |
2020-003515-10: To Study Aqueous Humor Composition and Retinal Imaging Features in Response to Anti-VEGF in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema STUDIE BIOMARKERŮ INHIBITORŮ VEGF ZKOUMAJÍCÍ VZTAH MEZI SLOŽENÍM KOMOROVÉ VODY A MULTIMODÁLNÍMI SNÍMKY SÍTNICE PŘI VLHKÉ FORMĚ VĚKEM PODMÍNĚNÉ MAKULÁRNÍ DEGENERACE A DIABETICKÉM MAKULÁRNÍM EDÉMU |
|
|
| Ongoing | 4 | 200 | RoW | Aflibercept, Solution for injection in pre-filled syringe, Eylea® | F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd | Treatment Naïve Neovascular Age-Related Macular Degeneration (nAMD) and Treatment Naïve diabetic macular edema (DME), nAMD is an eye disease particularly affects the center of sharp vision (e.g affects reading or driving). DME is a complication of diabetes and causes problem in vision (e.g blurred or wavy vision)., Diseases [C] - Eye Diseases [C11] | | | | |
ChiCTR1900022572: Clinical effectiveness of variable dosing regimen with intravitreal conbercept for diabetic macular edema: a randomized controlled trial |
|
|
| Not yet recruiting | 4 | 105 | | 1+prn ;3+prn ;3+q2m | Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University; Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, 首都医科大学附属北京同仁医院 | diabetic macular edema | | | | |
NCT03999125: Anti-VEGF Therapy Versus Dexamethasone Implant for DME |
|
|
| Not yet recruiting | 4 | 150 | Europe | Aflibercept,, Ranibizumab, Dexamethasone Implant, Laser, Ranibizumab Injection, Dexamethasone Implant, Aflibercept, Laser, Ozurdex Drug Implant Product | Sudhalkar Eye Hospital | Clinically Significant Macular Edema Due to Diabetes Mellitus | 06/21 | 06/23 | | |
NCT04464694: Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema |
|
|
| Not yet recruiting | 4 | 142 | RoW | Ranibizumab, Lucentis, Sham injection, Pars plana vitrectomy, Vitrectomy | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Novartis | Proliferative Diabetic Retinopathy, Diabetic Macular Edema | 12/21 | 06/22 | | |
| Recruiting | 4 | 2323 | | Ranibizumab | Zhongshan Ophthalmic Center, Sun Yat-sen University; Zhongshan Ophthalmic Center, Novartis Beijing | Age-Related Macular Degeneration/Diabetic Macular Edema/Macular Edema secondary to Retinal Vein Occlusion | | | | |
OPEAXE, ChiCTR2000036080: Evaluation of the efficacy of dexamethasone sustained-release implant (Ozurdex) in patients with proliferative diabetic retinopathy complicated with diabetic macular edema (vitrectomy / silicone oil filling and silicone oil removal) in combination |
|
|
| Not yet recruiting | 4 | 200 | | Intraoperative dexamethasone sustained release implant ;none | Beijing aier intech eye hospital; Beijing aier intech eye hospital, Self-financing | Diabetic retinopathy | | | | |
STAMP, NCT03832179: Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification |
|
|
| Recruiting | 4 | 32 | US | Bevacizumab, Avastin, Ranibizumab, Lucentis, Aflibercept, Eylea, Ozurdex, Dexamethasone implant | Bay Area Retina Associates, Allergan | Diabetic Macular Edema, Cataract | 07/22 | 10/22 | | |
2018-004785-33: Study to Evaluate the Efficacy and Safety of OZURDEX® in Treatment Naïve Patients with Diabetic Macular Edema Estudio para evaluar la eficacia y seguridad de OZURDEX® ) en pacientes sin tratamiento previo con edema macular diabetic |
|
|
| Not yet recruiting | 4 | 150 | Europe | OZURDEX®, Intravitreal implant in applicator, OZURDEX® | Allergan Pharmaceuticals International Limited, Allergan Pharmaceuticals International Limited | Diabetic Macular Edema Edema Macular Diabético, Diabetic Macular Edema Edema Macular Diabético, Diseases [C] - Eye Diseases [C11] | | | | |
REBEL, NCT04991350: Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema |
|
|
| Terminated | 4 | 5 | RoW | Intravitreal ranibizumab, Lucentis, Intravitreal bevacizumab, Avastin | Cairo University | Diabetic Macular Edema, Macular Ischemia, Diabetic Retinopathy, Vascular Endothelial Growth Factor Overexpression | 09/22 | 11/22 | | |
ChiCTR2100043460: A short-term clinical trial of intravitreal dexamethasone implant (OZURDEX) in treatment of persistent diabetic macular edema |
|
|
| Recruiting | 4 | 30 | | intravitreal dexamethasone implant (OZURDEX) ;intravitreal dexamethasone implant (OZURDEX) combined with laser photocoagulation | Shanghai Tongji Hospital; Shanghai Tongji Hospital, Shanghai Tongji Hospital, clinical research and breeding program | Diabetic Macular Edema | | | | |
DETeR, NCT04563299: Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections |
|
|
| Terminated | 4 | 10 | US | Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate | Retina Vitreous Associates of Florida, Ocular Therapeutix, Inc. | Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion | 02/23 | 02/23 | | |
ChiCTR2100043531: A Clinical study of decreasing the number of injections of Ranibizumab in diabetic macular edema by using doxium |
|
|
| Recruiting | 4 | 72 | | calcium dobesilate (doxium） ;placebo | The First Affiliated Hospital of Jinan University; The First Affiliated Hospital of Jinan University, Bethune Charitable Foundation | Diabetic macular edema | | | | |
ChiCTR2200059909: Intervention study of intravitreal injection of conbercept in combination with dexamethasone intravitreal implants (Ozurdex) for the treatment of diabetic macular edema |
|
|
| Recruiting | 4 | 80 | | Conbercept intravitreal injection (3+PRN regimen) ;The first treatment was combined with conbercept intravitreal injection and Ozurdex intravitreal implant, followed by treatment with the control group (3 +PRN regimens). | Joint Shantou International Eye Center of Shantou University and the Chinese University of Hong Kong; Level of the institution：, Chaozhou Science and Technology Program Project (210531174603743) | diabetic macular edema | | | | |
PRECISION, NCT04411693: Comparative Study of Dexamethasone Implant to Intravitreal Aflibercept in Subjects With Diabetic Macular Edema |
|
|
| Completed | 4 | 23 | US | Dexamethasone implant, Ozurdex, Aflibercept, Eylea | The Cleveland Clinic, Allergan | Diabetic Macular Edema | 01/24 | 01/24 | | |
NCT05610488: Intravitreal Faricimab in Diabetic Macular Edema With Limited Response to Aflibercept |
|
|
| Not yet recruiting | 4 | 30 | NA | FARICIMAB 6 Mg in 0.05 mL INTRAVITREAL INJECTION, SOLUTION [VABYSMO], Vabysmo | Vista Klinik | Diabetic Macular Edema | 12/23 | 12/23 | | |
| Recruiting | 4 | 168 | Canada | Intravitreal aflibercept, Eylea | Unity Health Toronto | Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Macular Edema | 02/24 | 02/24 | | |
| Recruiting | 4 | 168 | Canada | Intravitreal ranibizumab | Unity Health Toronto | Age Related Macular Degeneration, Diabetic Macular Edema, Macular Edema, Retinal Vein Occlusion | 02/24 | 02/24 | | |
NCT05861466: Comparative Study Between IVI of Ranibizumab With and Without Prior ACP in Patients With DME Using OCT-A |
|
|
| Recruiting | 4 | 100 | RoW | intra-vitreal injection of Ranibizumab, anterior chamber paracentesis | Ain Shams University | Diabetic Macular Edema | 04/24 | 04/24 | | |
INSITE-DME, NCT05610319: Treat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial |
|
|
| Recruiting | 4 | 446 | Europe, Canada, US, RoW | Faricimab | McMaster University, Hoffmann-La Roche | Diabetic Macular Edema | 08/26 | 08/26 | | |
NCT06305143: Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic Retinopathy |
|
|
| Recruiting | 4 | 58 | RoW | Conbercept | Shanghai Eye Disease Prevention and Treatment Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Diabetic Macular Edema | 12/24 | 07/25 | | |
VISION-AF, NCT05511038: A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema |
|
|
| Completed | 4 | 100 | RoW | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer | Diabetic Macular Edema | 04/24 | 04/24 | | |
ChiCTR2100046527: The clinical research of Yiqi Yangyin Huoxue Lishui combined with aflibercept on diabetic macular edema |
|
|
| Recruiting | 4 | 100 | | Treatment with aflibercept ;Yiqi Yangyin Huoxue Lishui combined with aflibercept | Chongqing Aier Eye Hospital; Chongqing Aier Eye Hospital Co. Ltd, Chongqing Science and Health Union | diabetic macular edema | | | | |
ChiCTR2200064404: Intravitreal Conbercept for diabetic macular edema in real-world clinical practice in China: a multi-center, observational study |
|
|
| Not yet recruiting | 4 | 300 | | None | Shanghai General Hospital; Shanghai General Hospital, China International Medical Foundation | Diabetic Macular Edema | | | | |
NCT05990829: Compare the Efficacy of VItrectomy Combined With DExamethasone Implant Versus With Aflibercept in DME Patients Diagnosed by Intraoperative OCT (the VIDEO Study): Study Protocol for a Randomized Controlled Trial |
|
|
| Recruiting | 4 | 64 | RoW | Ozurdex, Aflibercept | Tianjin Medical University Eye Hospital, Abbvie Pharmaceutical Trading (Shanghai) Co., Ltd. | Diabetic Macular Edema, Pars Plana Vitrectomy, Dexamethasone Intravitreal Implant, Intraoperative Optical Coherence Tomography | 10/24 | 04/25 | | |
NCT04469595: A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME) |
|
|
| Active, not recruiting | 4 | 300 | US | Iluvien 0.19 MG Drug Implant, ILUVIEN, Aflibercept, Eylea | Alimera Sciences | Diabetic Macular Edema | 12/24 | 12/24 | | |
ChiCTR2300073357: The efficacy of anti-VEGF combined with dexamethasone implant in the treatment of refractory diabetic macular edema |
|
|
| Recruiting | 4 | 60 | | switch to other anti-VEGF ;intravitreal dexamethasone implant combined with anti-VEGF | Nanning Aier Eye Hospital; Nanning Aier Eye Hospital, self-funded | refractory diabetic macular edema | | | | |
NCT05224102: A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema |
|
|
| Recruiting | 4 | 218 | US, RoW | Faricimab, VABYSMO™, RO6867461, RG7716 | Genentech, Inc. | Diabetic Macular Edema | 11/26 | 11/26 | | |
EMMA, NCT04910503: Medico Economic Evaluation of Fluocinolone Acetonide Implant Versus Dexametheasone Implant in Resistant Diabetic Macular Oedema |
|
|
| Recruiting | 4 | 106 | Europe | Dexamethasone intravitreal implant, Fluocinolone Acetonide Intravitreal Implant | Centre Hospitalier Universitaire Dijon | Diabetic Macular Edema | 04/30 | 04/30 | | |
2013-000031-27: Injections into the eye (drug Lucentis) in diabetic patients in whom no further treatment is currently available in clinic when they have developed swelling of the centre of the macula associated with lack of blood supply. |
|
|
| Ongoing | 3/4 | 80 | Europe | Lucentis, Lucentis, Lucentis | Moorfields Eye Hospital, Fight for Sight, Novartis Pharmaceuticals UK Ltd | Ischaemic Diabetic Macular Oedema | | | | |
